JPMorgan raised the firm’s price target on Globe Life to $136 from $133 and keeps an Overweight rating on the shares. The firm says the company’s Q4 results affirm its positive view of the stock. The results were marked by upside in earnings, strong fundamentals in both the life and health divisions, and an increase in 2024 guidance, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GL: